Obesity/Overweight | Landscape & Forecast | Disease Landscape & Forecast

Publish date: June 2019

Login to access report

Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Compounding this problem is the fact that available treatments do not have desirable risk-benefit profiles at low prices; in addition, few novel agents are in development for obesity. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. However, such is the prevalence of obesity that, even if such an agent is developed and approved, payers will likely need to control access to it to limit the impact on finite healthcare budgets.

Questions Answered:

  • Which metabolic and central pathways have high potential as drug targets?
  • What is the prevalence of obesity in the major pharmaceutical markets under study?
  • How is obesity currently treated? What do experts think about Novo Nordisk’s Saxenda as a treatment for obese/overweight patients?
  • What is the current level of unmet need according to obesity experts? How will this need be addressed over the 2018-2028 forecast period?
  • What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
  • How will the obesity market evolve over the next ten years?

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Obesity / Overweight?
        • What Factors Are Constraining the Market for Obesity / Overweight?
      • Drug-Class-Specific Trends
        • Fixed-Dose Combinations
        • Serotonin Receptor Agonists
        • Noradrenergic Anorectic Agents
        • GLP-1 Receptor Agonists
        • Lipase Inhibitors
        • Off-Label Prescription Drugs
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
      • Natural History
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
        • Key Updates
      • Epidemiology Populations
        • Total Prevalence of Obesity and Overweight
        • Obesity Subtypes by Disease Severity
        • Drug-Treatable Overweight Cases
        • Diagnosed Prevalent Cases of Obesity and Overweight
        • Drug-Treated Prevalent Cases of Obesity and Overweight
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Lipase Inhibitors
        • Noradrenergic Anorectic Agents
        • Serotonin Receptor Agonists
        • GLP-1 Receptor Agonists
        • Fixed-Dose Combinations
        • Off-Label Prescription Drugs
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Obesity / Overweight
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • GLP-1 Receptor Agonists
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Obesity / Overweight
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Obesity Bibliography

Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.); Sunali D. Goonesekera, SM

Rameshwar Prajapati, (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications. Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.